Podcast Atlas
source Episode summary Updated 2026-08-06 Tags: Podcast, Biotech, Pharma, China, Investing

156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开

Summary

This [[QizhulouYanBinke|起朱楼宴宾客]] episode has [[DavidWeng|大卫翁]] and [[XiaoPTeacher|小P老师]] review the 2025 China innovation-drug boom and offer a source-dated 2026 outlook. The source argues that record Chinese BD activity came from Multinational Pharma Patent-Cliff Anxiety, Chinese R&D cost and talent advantages, improving [[ClinicalDataTrustRebuilding|clinical-data trust]], and real technical progress rather than only capital-market noise. Its forward-looking frame is Biotech BD Data Validation Phase: after headline deals, investors and companies must watch clinical readouts, PFS/OS, milestone execution, global cost-sharing, commercial infrastructure, and payment policy.

Key Claims

  • The episode says 2025 Chinese innovation-drug BD reached a historic peak, with transaction value above $130 billion, China exceeding the United States in total BD amount, and Chinese deals representing about half of global BD value in the source’s account.
  • Deal structure matters as much as headline amount. The source treats 2025 as a shift toward [[PlatformLevelBiotechBD|platform-level and company-level BD]], where MNCs buy access to many molecules or technology capability rather than one isolated asset.
  • [[SanShengPharma|三生制药]] with [[Pfizer|辉瑞]], [[HengruiPharma|恒瑞医药]] with [[GSK|GSK]], and [[InnoventBiologics|信达生物]] with [[TakedaPharmaceutical|武田制药]] are used as major China-outbound BD cases.
  • MNC demand is tied to Multinational Pharma Patent-Cliff Anxiety. [[Merck|默沙东]]’s [[Keytruda|K药]] and HPV-vaccine pressure are used to show why large pharma companies need new future cash-flow sources.
  • Chinese supply is tied to cheaper and faster early-research inputs, dense scientific talent, and more credible clinical execution, which together extend China Biotech Asset Repricing beyond a simple “cheap China assets” story.
  • The source revisits [[Akeso|康方生物]] and [[SummitTherapeutics|Summit]] through [[PD1VEGFBispecific|PD-1/VEGF bispecific]] data. It distinguishes strong PFS from still-unproven or less spectacular OS, making Progression-Free vs Overall Survival central to 2026 interpretation.
  • Clinical Data Trust Rebuilding is a key precondition for large BD. The source says earlier China clinical data faced trust problems around enrollment and CRO execution, while standards, experience, and some overseas trial work have reduced that skepticism.
  • The [[InnoventBiologics|信达生物]] and [[TakedaPharmaceutical|武田制药]] cooperation is presented as a more ambitious model than ordinary license-out: global cost sharing and profit sharing around a [[PD1IL2Bispecific|PD-1/IL-2 bispecific]] signal confidence in both the molecule and international development.
  • The episode emphasizes that drug innovation is not target arithmetic. PD-1/IL-2 Bispecific, PD-1/VEGF Bispecific, [[TCellEngagers|TCEs]], PROTAC-like degraders, and other multifunctional molecules work only if biology, localization, toxicity, and treatment window improve together.
  • [[TCellEngagers|TCEs]] are framed as serious competitors to parts of [[CARTCellTherapy|CAR-T]], especially when [[JohnsonAndJohnson|Johnson & Johnson]]’s multiple-myeloma portfolio pressures [[LegendBiotech|Legend Biotech]]. In Vivo CAR-T still remains attractive if it can simplify manufacturing and dosing.
  • [[GLP1Agonists|GLP-1]] competition is treated as commercial execution as well as pharmacology: [[NovoNordisk|Novo Nordisk]]’s sales disappointment and cautious capacity expansion gave [[EliLilly|Eli Lilly]] room, while discontinuation rebound keeps lifestyle change relevant.
  • Policy is moving from pure price pressure toward innovation support. The source highlights the [[InnovativeDrugCommercialInsuranceCatalog|commercial-insurance innovative-drug catalog]], differentiated payment tolerance, local industrial support, and possible first-in-class pricing flexibility.
  • 2026 is presented as a validation year: BD projects from 2023-2025 should begin producing clinical data, milestone progress, commercialization evidence, and clearer answers about whether Chinese companies license out, co-develop, or build [[ChinaBiotechGlobalization|global pharma capability]].
  • [[RadiopharmaceuticalDrugConjugates|RDCs]] and [[SmallNucleicAcidDrugs|small nucleic acid drugs]] are highlighted as newer modality watch items. RDCs need isotope, hospital-distance, and radiation-control supply chains, while small nucleic acid drugs intervene at the RNA layer and currently concentrate around liver/metabolic targets.
  • Alzheimer’s disease and neuropsychiatric drugs remain a “black hole” in the source’s frame because biology is still insufficiently understood.

Key Quotes

“BD” - source shorthand for the deal-making route that made Chinese innovation drugs visible globally.

“PFS、OS” - the episode’s recurring distinction between delayed progression and patients living longer.

“星辰大海” - the title’s optimistic but still unproven globalization frame for Chinese drug companies.

Connections

Contradictions

  • No direct contradiction found with existing wiki content.
  • The source qualifies vol.117.生物医药的2025：抄底中国、研发焦虑和新王继位 rather than reversing it: vol.117 warned that Chinese asset enthusiasm still needed clinical proof; this episode says 2026 is when that proof begins to matter more than BD headlines.
  • The source qualifies PD-1/VEGF Bispecific by separating strong PFS from still-debated OS, which is compatible with earlier pages that recorded Merck’s demand for survival evidence.
  • The source qualifies T-Cell Engagers by showing that TCEs can pressure CAR-T in specific commercial and clinical contexts, even if earlier pages framed them as generally cheaper and weaker than CAR-T.